 | |
| Clinical data | |
|---|---|
| Other names | 2,5-Dimethoxy-4-allylthiophenethylamine; 4-Allylthio-2,5-dimethoxyphenethylamine |
| Routes of administration | Oral[1] |
| Drug class | Serotonergic psychedelic;Hallucinogen |
| ATC code |
|
| Pharmacokinetic data | |
| Duration of action | 4–6 hours[1] |
| Identifiers | |
| |
| CAS Number |
|
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C13H19NO2S |
| Molar mass | 253.36 g·mol−1 |
| 3D model (JSmol) | |
| Melting point | 193 to 194 °C (379 to 381 °F) |
| |
| |
2C-T-16, also known as4-allylthio-2,5-dimethoxyphenethylamine, is apsychedelic drug. It was originally named byAlexander Shulgin as described in his bookPiHKAL (Phenethylamines i Have Known And Loved), however while Shulgin began synthesis of this compound he only got as far as thenitrostyrene intermediate, and did not complete the final synthetic step.[2] Synthesis of 2C-T-16 was finally achieved byDaniel Trachsel some years later.[3]
Daniel Trachsel reported 2C-T-16 as showing similar psychedelic activity to related compounds, with a dose range of 10–25 mg and a duration of 4–6 hours,[1]: 788–789 making it around the same potency as the better-known saturated analogue2C-T-7, but with a significantly shorter duration of action.
Binding studiesin vitro showed 2C-T-16 to have abinding affinity of 44 nM at5-HT2A and 15 nM at5-HT2C.[1]: 791 2C-T-16 and related derivatives are potentpartial agonists of the 5-HT1A, 5-HT2A, 5-HT2B and 5-HT2C receptors and induce ahead-twitch response in mice.[4]
As of October 31, 2016, 2C-T-16 is a controlled substance (Schedule III) in Canada.[5]
